A Study Comparing the Efficacy of Pataday® Once Daily Rel... | NCT05265910

Status Module

Label	Type	Description	Intervention Names
Pataday® Once Daily Relief Extra Strength and Placebo tablet	Active Comparator	Pataday® Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%) will be administered bilaterally and Placebo tablet will be administered orally (within 5 minutes of eyedrop) at Visits 3 and 4a.	Drug: olopatadine hydrochloride ophthalmic solution 0.7% Drug: Placebo
Tears Naturale® II and Claritin® Tablet 24-Hour	Active Comparator	Tears Naturale® II will be administered bilaterally and Claritin® Tablet 24-Hour (loratadine 10 mg) will be administered orally (within 5 minutes of eyedrop) at Visits 3 and 4a.	Drug: loratadine 10 mg Drug: Tears Naturale

Name	Type	Description	Arm Group Labels	Other Names
olopatadine hydrochloride ophthalmic solution 0.7%	Drug	Pataday® Once Daily Relief Extra Strength (eyedrop)	Pataday® Once Daily Relief Extra Strength and Placebo tablet

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Ocular itching 3(±1) minutes post-CAC at Visit 3	Ocular itching evaluated by the subject at 3(±1) minutes post-CAC (0-4 on the Ocular Itching scale with 4 being the worst, allowing half unit increments) at Visit 3.	3(±1) minutes post-CAC on Day 1 (Visit 3)
Ocular itching 3(±1) minutes post-CAC at Visit 4b	Ocular itching evaluated by the subject at 3(±1) minutes post-CAC (0-4 on the Ocular Itching scale with 4 being the worst, allowing half unit increments) at Vi sit 4b.	3(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Ocular itching 5(±1) minutes post-CAC at Visit 3	Ocular itching evaluated by the subject at 5(±1) minutes post-CAC (0-4 on the Ocular Itching scale with 4 being the worst, allowing half unit increments) at Visit 3.	5(±1) minutes post-CAC on Day 1 (Visit 3)
Ocular itching 5(±1) minutes post-CAC at Visit 4b	Ocular itching evaluated by the subject at 5(±1) minutes post-CAC (0-4 on the Ocular Itching scale with 4 being the worst, allowing half unit increments) at Visit 4b.	5(±1) minutes post-CAC at Visit 4b (24 hours from Visit 4a; Day 15±3)
Ocular itching 7(±1) minutes post-CAC at Visit 3	Ocular itching evaluated by the subject at 7(±1) minutes post-CAC (0-4 on the Ocular Itching scale with 4 being the worst, allowing half unit increments) at Visit 3.	7(±1) minutes post-CAC on Day 1 (Visit 3)
Ocular itching 7(±1) minutes post-CAC at Visit 4b	Ocular itching evaluated by the subject at 7(±1) minutes post-CAC (0-4 on the Ocular Itching scale with 4 being the worst, allowing half unit increments) at Visit 4b.

Secondary Outcomes

Measure	Description	Time Frame
Secondary Efficacy Measures 7(±1) minutes post-CAC at Visit 3; Conjunctival Redness	Conjunctival redness evaluated by the investigator (0-4 on the Ocular Redness scale with 4 being the worst, allowing half unit increments) at Visit 3.	7(±1) minutes post-CAC on Day 1 (Visit 3)
Secondary Efficacy Measures 15(±1) minutes post-CAC at Visit 3; Conjunctival Redness

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Each subject must:

Be at least 18 years of age at Visit 1 of either gender and any race;
Provide written informed consent and sign the HIPAA form;
Be willing and able to follow all instructions and attend all study visits;
Have a history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, and/or tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at Visit 1 or within the last 24 months;
Be able and willing to avoid all disallowed medications for the appropriate washout period and during the study (see exclusion 6);
Be able and willing to discontinue wearing contact lenses for at least 72 hours prior to Visit 1 and during the study trial period;
(for females capable of becoming pregnant) agree to have urine pregnancy testing performed at screening (must be negative) and exit visit; must not be lactating; and must agree to use a medically acceptable form of birth control throughout the study duration. Women considered capable of becoming pregnant include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy);
Have a calculated best-corrected visual acuity of 0.7 logMAR or better in each eye as measured using an ETDRS chart;
Have a positive bilateral post-CAC reaction (defined as having scores of ≥2 ocular itching and ≥2 conjunctival redness) within 10 (±2) minutes of instillation of the last titration of allergen at Visit 1;
Have a positive bilateral post-CAC reaction (defined as having scores of ≥2 ocular itching and ≥2 conjunctival redness) for at least two out of the first three time points following the challenge at Visit 2.

Exclusion Criteria:

Each subject must not:

1. Have known contraindications or sensitivities to the use of the investigational product or any of its components; 2. Have any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters (including but not limited to narrow angle glaucoma, clinically significant blepharitis, follicular conjunctivitis, iritis, pterygium, history of corneal transplantation or a diagnosis of dry eye); 3. Have had ocular surgical intervention within three (3) months prior to Visit 1 or during the study and/or a history of refractive surgery within the past six (6) months; 4. Have a known history of retinal detachment, diabetic retinopathy, or active retinal disease; 5. Have the presence of an active ocular infection (bacterial, viral, or fungal) or positive history of an ocular herpetic infection at any visit; 6. Use any of the following disallowed medications during the period indicated prior to Visit 1 and during the study: 7 Days

systemic or ocular H1-antihistamine, H1-antihistamine/mast cell stabilizers, H1-antihistamine-vasoconstrictor drug combinations;
decongestants;
monoamine oxidase inhibitors
all other topical ophthalmic preparations (including artificial tears)
lid scrubs;
topical prostaglandins or prostaglandin derivatives
ocular, topical, or systemic nonsteroidal anti-inflammatory drugs (NSAIDs, including baby aspirin (81 mg)) 14 Days
inhaled, ocular, topical, or systemic corticosteroids or mast cell stabilizers; 45 Days
depo-corticosteroids; Note: Currently marketed over-the-counter anti-allergy eye drops (i.e. anti-histamine/vasoconstrictor combination products such as Visine®-A®) may be administered to subjects by trained study personnel at the end of Visits 1, 2 and 4b after all evaluations are completed.

7. Have any significant illness (e.g. any autoimmune disease requiring therapy, severe cardiovascular disease [including arrhythmias] the investigator feels could be expected to interfere with the subject's health or with the study parameters and/or put the subject at any unnecessary risk (includes but is not limited to: poorly controlled hypertension or poorly controlled diabetes, a history of status asthmaticus, organ transplants, a known history of persistent moderate or severe asthma, or a known history of moderate to severe allergic asthmatic reactions to any of the study allergens; 8. Have received allergy immunotherapy within the last 2 years; 9. Manifest signs or symptoms of clinically active allergic conjunctivitis in either eye at the start of Visits 1, 2, or 3 (defined as the presence of any itching or >1 [greater than 1] redness in any vessel bed); 10. Have a history of glaucoma; 11. Have planned surgery (ocular or systemic) during the trial period or within 30 days after; 12. Have used an investigational drug or medical device within 30 days of the study or be concurrently enrolled in another investigational product trial; 13. Be a female who is currently pregnant, planning a pregnancy, or lactating.

ID	Term
D003231	Conjunctivitis
D003229	Conjunctival Diseases
D005128	Eye Diseases
D006969	Hypersensitivity, Immediate
D006967	Hypersensitivity
D007154	Immune System Diseases

ID	Term
D003533	Cyproheptadine
D003986	Dibenzocycloheptenes
D001567	Benzocycloheptenes
D011084	Polycyclic Aromatic Hydrocarbons
D006841	Hydrocarbons, Aromatic
D006844	Hydrocarbons, Cyclic
D006838	Hydrocarbons
D009930	Organic Chemicals
D010880	Piperidines
D006573	Heterocyclic Compounds, 1-Ring
D006571	Heterocyclic Compounds
D011083	Polycyclic Compounds